Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
1998-08-12
2001-12-04
Travers, Russell (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S529000, C514S561000, C514S568000, C514S646000, C514S647000, C514S679000
Reexamination Certificate
active
06326402
ABSTRACT:
The present invention is in the field of biochemistry and pharmacology. Specifically, the present invention relates to methods for inhibiting viral replication and treating viral infections by administering a pharmaceutically effective amount of a compound capable of binding microtubules or inhibiting microtubule formation or tubulin polymerization such as diiodo thyronine analogues. The invention also relates to pharmaceutical compositions comprising the same.
BACKGROUND OF THE INVENTION
The high degree of infectiousness and fast reproduction cycle of viruses within host organisms make viruses a nuisance and a health hazard. There is no simple treatment of viral diseases. Viruses are not susceptible to antibiotics. The only available treatment of viral diseases is chemotherapy utilizing viral replication inhibitors in host cells
The Merck Manual,
170 (1982), 14th Ed.). Examples of these chemical agents are idoxuridine, acyclovir, ribavirin, vidarabine, gancyclovir, adenine arabinoside (ABA-A) and AZT. These, and other viral replication inhibitors, however, are cytotoxic, hepatotoxic, neurotoxic, nephrotoxic and teratogenic (
Virus Diseases,
1-6 (1978), Crown Publishers, N.Y.).
Human immunodeficiency virus (HIV) infections known as acquired immunodeficiency syndrome (AIDS) presently constitute a worldwide health hazard. HIV infections are almost always fatal due to a weakened immunoresistance, leading to opportunistic infections, malignancies and neurologic lesions. There are few effective treatments for AIDS other than the treatment of the opportunistic infections, neoplasms and other complications. Available cytostatic (AZT) and antiviral (acyclovir) drugs are extremely toxic and cause severe adverse reactions. Novel classes of protease inhibitors have not been satisfactorily studied over the long term to assure continued efficacy and to assess long term side effects. Thus it would be highly desirable to have available an effective and yet nontoxic treatment of viral diseases, in particular, AIDS.
Herpes simplex virus type-1 and 2 are also widespread infections. They may occur in AIDS patients as one of the opportunistic infections. Type-1 HSVstrain (HSV-1) commonly causes herpes labialism located on a lip, and keratitis, an inflammation of the cornea. Type-2 HSV is usually located on or around the genital area and is generally transmitted primarily by direct contact with herpetic sores or lesions. HSV-2 has been related to the development of uterine cancer. Herpes simplex virus is very infectious and is rapidly and easily transferable by contact. There is no specific therapy for this extremely painful viral infection. Current treatment of HSV infections is limited primarily to systemic administration of the above-mentioned antiviral drugs with corresponding adverse side affects. The antiviral agents used for treatment are non-selective inhibitors of HSV replication affecting the replication of normal cells as well. Therefore, when used in doses large enough to inactivate all of the active herpes viruses dormant in the sensory ganglia, these compounds may also be highly disruptive to host cell DNA replication. Thus, it would be advantageous to have available non-toxic treatment of HSV infections.
Cytomegalovirus (CMV), a dangerous co-infection of HIV, is a subgroup of highly infectious viruses having the propensity for remaining latent in man. CMVs are very common among the adult population and as many as 90% of adults have been exposed to and experienced CMV infections. CMVs are normally present in body liquids such as blood, lymph, saliva, urine, feces, milk, etc. CMV infections may cause abortion, stillbirth, postnatal death from hemorrhage, anemia, and severe hepatic or CNS damage. Particularly dangerous are CMV infections afflicting AIDS patients, where CMV may cause pulmonary, gastrointestinal or renal complications. There is no specific therapy for CMV infection. Unlike many other viruses, CMV is resistant to acyclovir, and to other known antiviral drugs. There is a great need to provide effective treatments for CMV infections.
Recently, it was discovered that agents that bind and/or inhibit the assembly or formation of microtubules are effective in inhibiting or preventing certain cancers. This is the subject of U.S. Ser. Nos. 08/655,267 and 08/833,272 filed on Jun. 4, 1996 and Apr. 3, 1997 respectively. The disclosures of both applications are herein expressly incorporated by reference in their entirety. Ketone diiodo thyronine analogues useful for treating cancer are the subject of U.S. Ser. No. 08/956,711 filed Oct. 23, 1997. The disclosure of this application is also herein expressly incorporated by reference in its entirety.
New classes of therapeutic agents providing new points of intervention for inhibiting or preventing viral infection and replication would be highly useful. It has been discovered that agents that bind and/or inhibit the assembly or formation of microtubules are effective in inhibiting or preventing viral infection and/or replication.
SUMMARY OF THE INVENTION
One aspect of the invention is a method for treating viral infections by administering a pharmaceutically effective amount of a compound capable of binding to microtubules or inhibiting microtubule formation. Preferably, the compound is substantially toxic only to cells that are infected with the target virus. Also, preferably, the compound is selectively permeable to cells infected with the target virus.
Exemplary compounds within the scope of the invention include diiodo thyronine analogues having no significant hormonal activity, particularly methyl 3,5-diiodo-4-(4′-methoxy phenoxy) benzoate (“DIME”), 1-[3,5-diiodo-4-(4′-methoxyphenoxy)-phenyl]-ethanone (“DIPE”) and 1-[3,5-diiodo-4-(4′-methoxyphenoxy)-phenyl]-propanone (“DIPP”).
The method for treating viral infections generally involves administering to a mammal an amount of a compound that binds to and inhibits microtubule formation that is effective to inhibit or prevent viral replication or to treat viral infection.
Yet another aspect of the invention is novel pharmaceutical compositions comprising a pharmaceutically effective amount of a compound capable of binding to microtubules or inhibiting microtubule formation. One such class of compounds are diiodo thyronine analogues having no significant hormonal activity, particularly methyl 3,5-diiodo-4-(4′-methoxy phenoxy) benzoate (“DIME”), 1-[3,5-diiodo-4-(4′-methoxyphenoxy)-phenyl]-ethanone (“DIPE”) and 1-[3,5-diiodo-4-(4′-methoxyphenoxy)-phenyl]-propanone (“DIPP”).
In one embodiment, diiodo thyronine analogues useful in the methods of the present invention are compounds having the structural formula:
and pharmaceutically acceptable salts thereof, wherein:
X=O, S, CH
2
, carboxy or absent;
Y=O or S;
R
1
=methyl or ethyl;
R
2
, R
3
, R
4
and R
5
are each independently selected from the group consisting of: H, (C
1
-C
4
) alky, (C
1
-C
4
) alkenyl, (C
1
-C
4
) alkynyl, hydroxy, (C
1
-C
4
) alkoxy and halogen; and
R
6
, R
7
, R
8
and R
9
are each independently selected from the group consisting of: H, (C
1
-C
4
) alkyl, (C
1
-C
4
) alkenyl, (C
1
-C
4
) alkynyl, hydroxy, (C
1
-C
4
) alkoxy, halogen, NO
2
and NH
2
.
In another illustrative embodiment, diiodo thyronine analogues useful in the methods of the present invention are compounds having the structural formula:
and pharmaceutically acceptable salts thereof, wherein:
X=O, S, CH
2
, carboxy or absent;
Y=O or S;
R
1
=methyl or ethyl;
R
2
, R
3
, R
4
and R
5
are each independently selected from the group consisting of: H, (C
1
-C
4
) alkyl, (C
1
-C
4
) alkenyl, (C
1
-C
4
) alkynyl, hydroxy, (C
1
-C
4
) alkoxy and halogen; and
R
7
and R
8
are each independently selected from the group consisting of: H, (C
1
-C
4
) alkyl, (C
1
-C
4
) alkenyl, (C
1
-C
4
) alkynyl, hydroxy, (C
1
-C
4
) alkoxy, halogen, NO
2
and NH
2
.
In a preferred embodiment of the invention the diiodo thyronine analogue is methyl 3,5-di
Kun Ernest
Mendeleyev Jerome
Halluin Albert P.
Howrey Simon Arnold & White , LLP
Octamer, Inc.
Smith J. David
Travers Russell
LandOfFree
Methods for treating viral infections using a compound... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating viral infections using a compound..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating viral infections using a compound... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2578374